Clinical Trial Update: Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating bendamustine and rituximab with or without orelabrutinib in mantle cell lymphoma. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Orelabrutinib (orelabrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Ruijin Hospital | Conditions: Mantle Cell Lymphoma (MCL) | Phase 3 | Status: RECRUITING